Literature DB >> 35840171

On the Importance of Considering Glycosylation When Evaluating Biologic Therapies.

Mathieu Lemaire1,2,3.   

Abstract

Entities:  

Keywords:  glycosylation; nephrotic syndrome; neuraminic acid; recombinant antibodies

Mesh：

Substances：

Year:  2022        PMID： 35840171      PMCID： PMC9342635          DOI： 10.1681/ASN.2022040461

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   14.978


× No keyword cloud information.
  4 in total

1.  Colloquium paper: uniquely human evolution of sialic acid genetics and biology.

Authors:  Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-05       Impact factor: 11.205

Review 2.  Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation.

Authors:  Darius Ghaderi; Mai Zhang; Nancy Hurtado-Ziola; Ajit Varki
Journal:  Biotechnol Genet Eng Rev       Date:  2012

3.  Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins.

Authors:  Darius Ghaderi; Rachel E Taylor; Vered Padler-Karavani; Sandra Diaz; Ajit Varki
Journal:  Nat Biotechnol       Date:  2010-07-25       Impact factor: 54.908

4.  Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.

Authors:  Pietro Ravani; Manuela Colucci; Maurizio Bruschi; Marina Vivarelli; Michela Cioni; Armando DiDonato; Paolo Cravedi; Francesca Lugani; Francesca Antonini; Marco Prunotto; Francesco Emma; Andrea Angeletti; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2021-09-20       Impact factor: 14.978
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.